Устоявшегося перевода нет. Для себя я бы перевела как "медикоэкономическое обоснование стоимости лекарственного средства".

As healthcare costs increase, a growing number of countries are formalizing requirements for biopharmaceutical coverage, pricing, and reimbursement. Even in countries with no national requirements, such as the U.S., payers are increasingly aware of cost and demand is high for health economic data to justify coverage and formulary decisions.
...
A GVD helps to elucidate, from a global perspective, the burden of illness associated with an underlying condition, as well as to demonstrate the product value in that particular condition. A customized GVD summarizes all of the core clinical, humanistic, and economic data for a biopharmaceutical product in a specific therapeutic area and builds a series of convincing arguments to communicate the product’s value proposition clearly and consistently. A GVD also presents value messages to internal stakeholders (e.g., reimbursement, marketing, health economics staff, and country affiliates) and payers to support product coverage and payment.
http://md.covance.com/insights/november 09/article.html

--------------------------------------------------
Note added at 1 hr (2011-06-28 19:05:43 GMT)
--------------------------------------------------

Через дефис: медико-экономическое.